Stock Price Movements, Campaigns, New Clinical Studies, and Approvals- Research Report on Actavis, Ariad Pharmaceuticals, DaVita, Celldex, and WellCare PR Newswire NEW YORK, December 5, 2013 NEW YORK, December 5, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Analysts' Corner announced new research reports highlighting Actavis plc (NYSE: ACT), Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA), DaVita Healthcare Partners Inc. (NYSE: DVA), Celldex Therapeutics, Inc. (NASDAQ: CLDX), and WellCare Health Plans, Inc. (NYSE: WCG). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Actavis plc Research Report On December 2, 2013, Actavis plc's stock (Actavis) rose 0.19%, ending the day at $163.38. Over the previous three trading sessions, shares of Actavis gained 0.52%, compared to the S&P 500 which declined 0.10% during the same period. The Full Research Report on Actavis plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/4997_ACT Ariad Pharmaceuticals, Inc. Research Report On December 2, 2013, Ariad Pharmaceuticals, Inc.'s (Ariad Pharmaceuticals) stock rose 1.86%, ending the day at $4.93. Over the previous three trading sessions, shares of Ariad Pharmaceuticals gained 5.34%, compared to the Nasdaq Composite which gained 0.68% during the same period. The Full Research Report on Ariad Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/161c_ARIA DaVita Healthcare Partners Inc. Research Report On November 27, 2013, DaVita Healthcare Partners Inc. (DaVita)'s wholly-owned subsidiary, DaVita Clinical Research (DCR), announced the launch of its "Inspired to Give" campaign, which shares experiences of people behind clinical research. DCR reported that the campaign began on November 12, 2013, and will continue up to February 2014. According to DCR, this campaign will include 18 videos featuring both clinical trial participants and researchers sharing their personal experiences related to clinical research. DCR added that videos will be available on YouTube, while 15-second versions will be viewable on Instagram. DCR Chief Scientific Officer Dr. Harry Alcorn, said, "We find that the driving force for most who participate in clinical trials is that they have someone close to them who has a disease or illness and they want to help that person. And in additional to being altruistic, trial participants ultimately play a key role in the future of health care by helping to develop medicine for others." The Full Research Report on DaVita Healthcare Partners Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/5986_DVA Celldex Therapeutics, Inc. Research Report On December 2, 2013, Celldex Therapeutics, Inc. (Celldex) announced that the Company has initiated a randomized study (METRIC) of Glembatumumab vedotin (CDX-011) in patients with metastatic triple negative breast cancers that over-express glycoprotein NMB (gpNMB). The Company informed that glembatumumab vedotin is an antibody-drug conjugate that targets and binds to gpNMB, a protein expressed in breast cancer which promotes the migration, invasion and metastasis of the disease. Further, Celldex informed that it is also highly expressed in triple negative breast cancers where it is associated with higher risk of recurrence. Thomas Davis, M.D., Senior Vice President and Chief Medical Officer of Celldex said, "Currently, patients with triple negative breast cancer have very limited treatment options and no targeted interventions. We believe gpNMB could be an important marker in breast cancer and that Glembatumumab vedotin holds significant potential as a possible targeted therapy for women facing this disease." Celldex informed that initial sites are now open to screen patients in the US, and additional sites in the US, Canada, and Australia, will open in early 2014. The Full Research Report on Celldex Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/b443_CLDX WellCare Health Plans, Inc. Research Report On November 26, 2013, WellCare Health Plans, Inc. (WellCare) announced that the Company was approved by the South Carolina Department of Health and Human Services (SCDHHS) to offer Medicaid in Charleston, Chesterfield, Greenwood, Kershaw, McCormick, and Spartanburg counties in the state, with effect from January 1, 2014. WellCare reported that with the addition of these six counties, it will provide Medicaid services to 45 out of 46 counties in South Carolina. Further, WellCare announced that membership from Carolina Medical Homes (CMH) is expected to transition to WellCare on January 1, 2014 as a result of alterations SCDHHS is making to its Healthy Connections Choices Medicaid managed care program and WellCare's pending purchase of certain assets from CMH. Dave Shafer, President, WellCare of South Carolina, commented, "This six county expansion will allow WellCare to provide Medicaid services to beneficiaries in nearly every county in South Carolina. It will also help us to ensure that almost all of the members transitioning from Carolina Medical Homes will be able to continue their care with their current primary care providers." The Full Research Report on WellCare Health Plans, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/be48_WCG EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to making mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. http://www.analystscorner.com/ SOURCE Analysts' Corner Contact: CONTACT PERSON: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
Stock Price Movements, Campaigns, New Clinical Studies, and Approvals- Research Report on Actavis, Ariad Pharmaceuticals,
Press spacebar to pause and continue. Press esc to stop.